Literature DB >> 2596829

How much difference does chromosome banding make? Adjustments in prevalence and mutation rates of human structural cytogenetic abnormalities.

E B Hook1, N P Healy, A M Willey.   

Abstract

A collaborative analysis was undertaken of 226 karyotypes with structural chromosome abnormalities diagnosed primarily with low level banding resolution, about 300 to 400 bands per karyotype. We estimate that in this series, use of low level banding was required to detect about 78% of pericentric inversions, about 51% of reciprocal translocations, about 47% of all balanced translocations, about 35% of unbalanced rearrangements other than rings, Robertsonian translocations and extra structurally abnormal chromosomes, about 11% of all unbalanced rearrangements, and about 35% of all structural abnormalities. Adjustment factors derived from these figures were applied to prevalence and mutation rates of structural mutation rates derived from published large scale studies of livebirths. Had low level banding been used in these earlier studies we estimate that the rate of all structural abnormalities would have been about 60% higher than those reported (3.8 per 1000 vs. 2.3 per 1000 in the original studies). The increase is much higher for balanced abnormalities, 75% (3.4 per 1000 vs. 1.9 per 1000), than for unbalanced abnormalities, 5% (0.42 per 1000 vs. 0.405 per 1000). The increase in mutation rates for de novo cytogenetic abnormalities was similarly, considerably higher after such adjustment: the rates per 100,000 gametes increased from 18.0 to 35.0 for balanced rearrangements, from 8.2 to 10.1 for unbalanced abnormalities and from 26.2 to 45.1 for all abnormalities. These estimates illustrate the difference even low level banding makes to detection of structural cytogenetic abnormalities and why contemporary studies using such methods cannot be compared with earlier large scale population studies or livebirths without some type of adjustment such as those suggested here.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2596829     DOI: 10.1111/j.1469-1809.1989.tb01790.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  6 in total

1.  Selective chromosome analysis in couples with two or more miscarriages: case-control study.

Authors:  Maureen T M Franssen; Johanna C Korevaar; Nico J Leschot; Patrick M M Bossuyt; Alida C Knegt; Klasien B J Gerssen-Schoorl; Cokkie H Wouters; Kerstin B M Hansson; Ron Hochstenbach; Kamlesh Madan; Fulco van der Veen; Mariette Goddijn
Journal:  BMJ       Date:  2005-06-28

2.  Estimates of the frequency of chromosome abnormalities detectable in unselected newborns using moderate levels of banding.

Authors:  P A Jacobs; C Browne; N Gregson; C Joyce; H White
Journal:  J Med Genet       Date:  1992-02       Impact factor: 6.318

3.  De novo balanced chromosome rearrangements and extra marker chromosomes identified at prenatal diagnosis: clinical significance and distribution of breakpoints.

Authors:  D Warburton
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

4.  Cytogenetic and epidemiological findings in Down syndrome, England and Wales 1989 to 1993. National Down Syndrome Cytogenetic Register and the Association of Clinical Cytogeneticists.

Authors:  D Mutton; E Alberman; E B Hook
Journal:  J Med Genet       Date:  1996-05       Impact factor: 6.318

5.  The children of parents exposed to atomic bombs: estimates of the genetic doubling dose of radiation for humans.

Authors:  J V Neel; W J Schull; A A Awa; C Satoh; H Kato; M Otake; Y Yoshimoto
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

6.  Evaluating the role of paternal factors in aetiology and prognosis of recurrent pregnancy loss: study protocol for a hospital-based multicentre case-control study and cohort study (REMI III project).

Authors:  Nadia du Fossé; Marie-Louise van der Hoorn; Michael Eikmans; Sebastiaan Heidt; Saskia le Cessie; Annemarie Mulders; Jan van Lith; Eileen Lashley
Journal:  BMJ Open       Date:  2019-11-14       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.